Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness
ByNancy A. Dreyer, PhD,Sebastian Schneeweiss, MD,Barbara J. McNeil, MD,Marc L. Berger, MD,Alec M. Walker, MD,Daniel A. Ollendorf, MPH,Richard E. Gliklich, MD,for the GRACE Initiative The GRACE principles lay out 3 questions to help healthcare providers, patients, and other decision makers evaluate the quality of noninterventional comparative effectiveness studies.

Do Drug Formulary Policies Reflect Evidence of Value?
ByPeter J. Neumann, ScD,Pei-Jung Lin, MS,Dan Greenberg, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD,Edward Mansley, PhD,Milton C. Weinstein, PhD,Allison B. Rosen, MD, ScD 
Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization
ByPamela B. Landsman, MPH, DrPH,Winnie Yu, PharmD,XiaoFeng Liu, PhD,Steven M. Teutsch, MD,Marc L. Berger, MD 
Indirect Cost of Ischemic Heart Disease to Employers
ByBruce Sherman, MD. Author Reply by Christine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD, MPH 
Indirect Cost of Ischemic Heart Disease to Employers
ByChristine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Steven M. Teutsch, MD, MPH,Albert I. Wertheimer, PhD, MBA,Marc L. Berger, MD 
The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia
ByRobert S. Epstein, MD, MS,Susan Garrahan,Linda Nelsen, MS,Pamela Laber,Eve Slater, MD,Marc L. Berger, MD